PSA-Werte, PSA-Verdopplungszeit, Gleason Score und Therapiestatus liefern keine Vorhersage zur Traceranreicherung von [68Ga]PSMA-HBED-CC bei von Patienten mit rezidiviertem und/oder metastasiertem PCA

Frederik A. Verburg; David Pfister; Natascha I. Drude; Felix M. Mottaghy; Florian F. Behrendt

doi:10.3413/Nukmed-0917-17-07

PSA-Werte, PSA-Verdopplungszeit, Gleason Score und Therapiestatus liefern keine Vorhersage zur Traceranreicherung von [⁶⁸Ga]PSMA-HBED-CC bei von Patienten mit rezidiviertem und/oder metastasiertem PCA

Translated title of the contribution: PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer

Frederik A. Verburg^*, David Pfister, Natascha I. Drude, Felix M. Mottaghy, Florian F. Behrendt

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Aim: To assess whether clinical prostate cancer (PCA) related factors and therapy status can predict the degree of tracer uptake on [Ga-68] PSMA-HBED-CC PET/CT.

Materials & methods: We retrospectively studied 124 patients with recurrent an/or metastatic PCA who underwent [Ga-68] PSMA-HBED-CC PET/CT. The maximum standardized uptake value (SUVmax) was determined in the prostate bed as well as in three size categories ( 5-15 mm, > 15 mm) in pelvic lymph node, extrapelvic lymph node, bone and visceral metastases.

Results: Significant positive correlations between lesion size and SUVmax were found in pelvic lymph node metastases > 5 - 5 -

Conclusion: Measured tracer uptake in [Ga-68] PSMA-HBED-CC PET/CT in patients with recurrent/metastasized prostate cancer is significantly influenced by lesion size as a result of partial volume effects in the very small lesions. Clinical indicators of aggressive prostate cancer behaviour such as PSA levels, PSA doubling time or the Gleason score of the primary tumour, as well as the androgen deprivation therapy, radiation therapy or chemotherapy status are not related to measured tracer uptake.

Translated title of the contribution	PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer
Original language	German
Pages (from-to)	225-232
Number of pages	8
Journal	Nuklearmedizin
Volume	56
Issue number	6
DOIs	https://doi.org/10.3413/Nukmed-0917-17-07
Publication status	Published - 2017

Keywords

PSA
PSA doubling time
Gleason score
prostate cancer
[Ga-68]PSMA-HBED-CC PET/CT
MEMBRANE ANTIGEN-EXPRESSION
DIFFERENTIATED THYROID-CANCER
GA-68-PSMA LIGAND PET/CT
INTRAEPITHELIAL NEOPLASIA
BIOCHEMICAL RECURRENCE
PSMA EXPRESSION
CELIAC GANGLIA
PRIMARY TUMOR
ADENOCARCINOMA
REMISSION

Access to Document

10.3413/Nukmed-0917-17-07

Cite this

@article{d5e6af6ac40c4048be1cf125774a3cb2,

title = "PSA-Werte, PSA-Verdopplungszeit, Gleason Score und Therapiestatus liefern keine Vorhersage zur Traceranreicherung von [68Ga]PSMA-HBED-CC bei von Patienten mit rezidiviertem und/oder metastasiertem PCA",

abstract = "Aim: To assess whether clinical prostate cancer (PCA) related factors and therapy status can predict the degree of tracer uptake on [Ga-68] PSMA-HBED-CC PET/CT.Materials & methods: We retrospectively studied 124 patients with recurrent an/or metastatic PCA who underwent [Ga-68] PSMA-HBED-CC PET/CT. The maximum standardized uptake value (SUVmax) was determined in the prostate bed as well as in three size categories ( 5-15 mm, > 15 mm) in pelvic lymph node, extrapelvic lymph node, bone and visceral metastases.Results: Significant positive correlations between lesion size and SUVmax were found in pelvic lymph node metastases > 5 - 5 -Conclusion: Measured tracer uptake in [Ga-68] PSMA-HBED-CC PET/CT in patients with recurrent/metastasized prostate cancer is significantly influenced by lesion size as a result of partial volume effects in the very small lesions. Clinical indicators of aggressive prostate cancer behaviour such as PSA levels, PSA doubling time or the Gleason score of the primary tumour, as well as the androgen deprivation therapy, radiation therapy or chemotherapy status are not related to measured tracer uptake.",

keywords = "PSA, PSA doubling time, Gleason score, prostate cancer, [Ga-68]PSMA-HBED-CC PET/CT, MEMBRANE ANTIGEN-EXPRESSION, DIFFERENTIATED THYROID-CANCER, GA-68-PSMA LIGAND PET/CT, INTRAEPITHELIAL NEOPLASIA, BIOCHEMICAL RECURRENCE, PSMA EXPRESSION, CELIAC GANGLIA, PRIMARY TUMOR, ADENOCARCINOMA, REMISSION",

author = "Verburg, {Frederik A.} and David Pfister and Drude, {Natascha I.} and Mottaghy, {Felix M.} and Behrendt, {Florian F.}",

year = "2017",

doi = "10.3413/Nukmed-0917-17-07",

language = "German",

volume = "56",

pages = "225--232",

journal = "Nuklearmedizin",

issn = "0029-5566",

publisher = "Georg Thieme Verlag",

number = "6",

}

PSA-Werte, PSA-Verdopplungszeit, Gleason Score und Therapiestatus liefern keine Vorhersage zur Traceranreicherung von [⁶⁸Ga]PSMA-HBED-CC bei von Patienten mit rezidiviertem und/oder metastasiertem PCA. / Verburg, Frederik A.; Pfister, David; Drude, Natascha I. et al.
In: Nuklearmedizin, Vol. 56, No. 6, 2017, p. 225-232.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - PSA-Werte, PSA-Verdopplungszeit, Gleason Score und Therapiestatus liefern keine Vorhersage zur Traceranreicherung von [68Ga]PSMA-HBED-CC bei von Patienten mit rezidiviertem und/oder metastasiertem PCA

AU - Verburg, Frederik A.

AU - Pfister, David

AU - Drude, Natascha I.

AU - Mottaghy, Felix M.

AU - Behrendt, Florian F.

PY - 2017

Y1 - 2017

N2 - Aim: To assess whether clinical prostate cancer (PCA) related factors and therapy status can predict the degree of tracer uptake on [Ga-68] PSMA-HBED-CC PET/CT.Materials & methods: We retrospectively studied 124 patients with recurrent an/or metastatic PCA who underwent [Ga-68] PSMA-HBED-CC PET/CT. The maximum standardized uptake value (SUVmax) was determined in the prostate bed as well as in three size categories ( 5-15 mm, > 15 mm) in pelvic lymph node, extrapelvic lymph node, bone and visceral metastases.Results: Significant positive correlations between lesion size and SUVmax were found in pelvic lymph node metastases > 5 - 5 -Conclusion: Measured tracer uptake in [Ga-68] PSMA-HBED-CC PET/CT in patients with recurrent/metastasized prostate cancer is significantly influenced by lesion size as a result of partial volume effects in the very small lesions. Clinical indicators of aggressive prostate cancer behaviour such as PSA levels, PSA doubling time or the Gleason score of the primary tumour, as well as the androgen deprivation therapy, radiation therapy or chemotherapy status are not related to measured tracer uptake.

AB - Aim: To assess whether clinical prostate cancer (PCA) related factors and therapy status can predict the degree of tracer uptake on [Ga-68] PSMA-HBED-CC PET/CT.Materials & methods: We retrospectively studied 124 patients with recurrent an/or metastatic PCA who underwent [Ga-68] PSMA-HBED-CC PET/CT. The maximum standardized uptake value (SUVmax) was determined in the prostate bed as well as in three size categories ( 5-15 mm, > 15 mm) in pelvic lymph node, extrapelvic lymph node, bone and visceral metastases.Results: Significant positive correlations between lesion size and SUVmax were found in pelvic lymph node metastases > 5 - 5 -Conclusion: Measured tracer uptake in [Ga-68] PSMA-HBED-CC PET/CT in patients with recurrent/metastasized prostate cancer is significantly influenced by lesion size as a result of partial volume effects in the very small lesions. Clinical indicators of aggressive prostate cancer behaviour such as PSA levels, PSA doubling time or the Gleason score of the primary tumour, as well as the androgen deprivation therapy, radiation therapy or chemotherapy status are not related to measured tracer uptake.

KW - PSA

KW - PSA doubling time

KW - Gleason score

KW - prostate cancer

KW - [Ga-68]PSMA-HBED-CC PET/CT

KW - MEMBRANE ANTIGEN-EXPRESSION

KW - DIFFERENTIATED THYROID-CANCER

KW - GA-68-PSMA LIGAND PET/CT

KW - INTRAEPITHELIAL NEOPLASIA

KW - BIOCHEMICAL RECURRENCE

KW - PSMA EXPRESSION

KW - CELIAC GANGLIA

KW - PRIMARY TUMOR

KW - ADENOCARCINOMA

KW - REMISSION

U2 - 10.3413/Nukmed-0917-17-07

DO - 10.3413/Nukmed-0917-17-07

M3 - Article

SN - 0029-5566

VL - 56

SP - 225

EP - 232

JO - Nuklearmedizin

JF - Nuklearmedizin

IS - 6

ER -